For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Alnylam Pharmaceuticals, Inc.

USPTO Granted Patents = 466

% Expired Patents = 12.9

CIPO Patents = 26

EPO Patents = 115

Trademarks = 28

Forward Citations = 5,498

Loading Chart...

Loading Chart...

235 inventors (with patents filed for the assignee):

Muthiah Manoharan (169 out of 327 patents)

Kallanthottathil G Rajeev (160 out of 199 patents)

Martin A Maier (114 out of 130 patents)

4. Kevin Fitzgerald (81 out of 83 patents)

5. Brian R Bettencourt (75 out of 81 patents)

6. Gregory Hinkle (74 out of 99 patents)

7. Stuart Milstein (70 out of 94 patents)

8. Akin Akinc (52 out of 62 patents)

9. Pamela Tan (45 out of 55 patents)

10. Klaus Charisse (44 out of 44 patents)

11. Hans-Peter Vornlocher (39 out of 53 patents)

12. Mark K Schlegel (38 out of 39 patents)

13. Jayaprakash K Nair (36 out of 43 patents)

14. Vasant R Jadhav (36 out of 47 patents)

15. William Querbes (35 out of 35 patents)

Core Competencies:

iRNA Compositions

Biodegradable Lipids

Modified RNA Agents

Angiopoietin-like 3

Transthyretin

Ketohexokinase

Superoxide Dismutase 1

Huntingtin

Complement Components

Oligonucleotide Conjugates

Cell Death-Inducing Factors

466 patents: Sort by Forward Citations

1. 12760308 - Compositions and methods for silencing SCN9A expression (2026-10-13),

2. 12735702 - ENDOSOMAL CLEAVABLE LINKERS (2026-09-15),

3. 12723247 - METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION (2026-09-01),

4. RE50996 - SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF (2026-08-18),

5. 12709751 - MANNAN BINDING LECTIN SERINE PEPTIDASE 2 (MASP2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF (2026-08-18),

6. 12709748 - HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF (2026-08-18),

7. 12692494 - SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF (2026-07-28),

8. 12680099 - Complement component C3 iRNA compositions and methods of use thereof for treating or preventing complement component C3-associated diseases (2026-07-14),

9. 12655430 - HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF (2026-06-16),

10. 12653893 - Carbohydrate conjugated RNA agents and process for their preparation (2026-06-16),

11. 12590305 - Complement component C5 iRNA compositions and methods of use thereof (2026-03-31),

12. 12584130 - Angiotensinogen (AGT) iRNA compositions and methods of use thereof (2026-03-24),

13. 12577564 - Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof (2026-03-17),

14. 12569511 - Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof (2026-03-10),

15. 12565653 - ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereof (2026-03-03),

Company Overview

Alnylam Pharmaceuticals, Inc., based in Cambridge, MA, is a leader in the development of RNA interference (RNAi) therapeutics. The company specializes in innovative treatments targeting genetic diseases by utilizing its proprietary technology platforms, which include iRNA compositions and biodegradable lipids. Alnylam's research focuses on critical areas such as transthyretin amyloidosis and Huntington's disease, aiming to address unmet medical needs through advanced therapeutic modalities.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

466 Patents

#9 in Cambridge, MA

#61 in Massachusetts

#1,031 in US

#2,051 in the World

Cambridge, MA, United States of America

Alnylam Pharmaceuticals, Inc.

Forward Citations = 5,498

235 inventors:

Muthiah Manoharan (169 out of 327 patents)

Kallanthottathil G Rajeev (160 out of 199 patents)

Martin A Maier (114 out of 130 patents)

4. Kevin Fitzgerald (81 out of 83 patents)

5. Brian R Bettencourt (75 out of 81 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Alnylam Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/alnylam-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…